Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Ixia CEO Quits; Misstated Academic Credentials, Age, Early Employment History

RELATED NEWS
Trade XXIA now with 

Ixia (XXIA: Quote) announced that Vic Alston has resigned as its President and CEO and as a member of its board following a determination by the company's audit committee that although he had attended Stanford University, he had misstated his academic credentials, incorrectly claiming to have received a B.S. and a M.S. in Computer Science, and had misstated his age and early employment history.

The company said it has appointed Errol Ginsberg, Ixia's chairman of the board, founder and former CEO as acting CEO, in addition to his current role as chief innovation officer, and Alex Pepe, senior vice president, strategy, as chief operating officer.

Ixia also reaffirmed its third quarter revenue guidance and expects revenue to be above the midpoint of its previously stated guidance range of $112 million to $117 million.

The company plans to commence a search to identify a permanent CEO.

Click here to receive FREE breaking news email alerts for Ixia and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Here is a list of interesting stocks to watch on December 19. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed below and many more have been researched already, and... Shares of OvaScience Inc. (OVAS) have had a strong run in 2014, rising over 370 percent year-to-date. And that's indeed a very impressive return delivered by the fertility treatment company, which suffered a setback last year when it had to suspend a U.S. trial of its flagship fertility treatment due to regulatory concerns raised by the FDA. Nike Inc., the world's largest athletic shoes and apparel maker, said Thursday after the markets closed that its second quarter profit rose 23% from last year, helped by higher revenue and improved gross margin. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.